The increased sensitivity of PARG-deficient cells to the anti-neoplastic agent HU that blocks replication supports the concept of PARG inhibition to potentialize cancer therapies relying on genotoxic drugs as previously proposed (6,14,63,64). The gene discussed is PARG; the disease is cancer.